Genetic prodrug activation therapy for pancreatic cancer

Annals of the New York Academy of Sciences

Volumn 880, Issue , 1999, Pages 319-325

  Rigg, A S ^a   Lemoine, N R ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; AMYGDALIN; BENZOIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; DOXIFLURIDINE; DRUG METABOLIZING ENZYME; ETOPOSIDE; FLUCYTOSINE; GANCICLOVIR; METHOTREXATE; PRODRUG; XANTHINE;

CLINICAL TRIAL; CONFERENCE PAPER; GAP JUNCTION; GENE ACTIVATION; GENE THERAPY; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; NONHUMAN; PANCREAS CANCER; PROMOTER REGION; PROTO ONCOGENE;

EID: 0032806082     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb09535.x     Document Type: Conference Paper

References (26)

1. 1. DEMATTEO, R.P. et al. 1997. Engineering tissue-specific expression of a recombinant adenovirus: selective transgene transcription in the pancreas using the amylase promoter. J. Surg. Res. 72: 155-161.
2. 2. VILE, R.G. & I.R, HART. 1993. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53: 962-967.
3. 3. HARRIS, J.D. et al. 1994. Gene therapy for cancer using tumor-specific prodrug activation. Gene Ther. 1: 170-175.
4. 4. RING, C.J.A. et al. 1996. Suicide gene expression induced in tumor cells transduced with recombinant adenoviral, retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther. 3: 1094-1103.
5. 5. HAYDEN, F.G. 1995. Antiviral agents. In Goodman and Gilman's The Pharmacological Basis of Therapeutics. J.G. Hardman et al., Eds.: 1191-1223. McGraw-Hill. New York.
6. 6. MAR, E.-C. et al. 1985. Inhibition of cellular DNA polymerase α and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J. Virol. 53: 776-780.
7. 7. MOOLTON, F.L. 1986. Tumor chemosensitivity conferred by inserting herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 46: 5276-5281.
8. 8. BLOCK, A. et al. 1997. Adenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors. Pancreas 15: 25-34.
9. 9. ROSENFELD, M.E. et al. 1997. Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene. Ann. Surg. 225: 609-620.
10. 10. AOKI, K. et al. 1997. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum. Gene Ther. 8: 1105-1113.
11. 11. YANG, L. et al. 1996. Gene therapy of metastatic pancreas cancer with intraperitoneal injections of concentrated retroviral herpes simplex thymidine kinase vector supernatant and ganciclovir. Ann. Surg. 224: 405-417.
12. 12. FREEMAN, S.M. et al. 1992. Tumor regression when a fraction of the tumor mass contains the HSV-TK gene. J. Cell. Biochem. 16: 47.
13. 13. FREEMAN, S.M. et al. 1993. The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53; 5274-5238.
14. 14. HUBER, B.W. et al. 1994. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminsase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. USA 91: 8302-8306.
15. 15. Bi, L.B. et al. 1993. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV-tk retroviral gene therapy. Hum. Gene Ther. 4: 725-731.
16. 16. DOMAIN, B.A. et al. 1993. Transport of 5-fluorouracil and uracil into human erythrocytes. Biochem. Pharmacol. 46: 503-510.
17. 17. FREEMAN, S.M. et al. 1995. Treatment of ovarian cancer using a gene-modified vaccine. Hum. Gene Ther. 6: 927-939.
18. 18. RAM, Z. et al. 1994. The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats. J. Neurosurg. 81: 256-260.
19. 19. FREEMAN, S.M. et al. 1995. The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells. Cancer Lett. 92: 167-174.
20. 20. MULLEN, C.A. et al. 1994. Tumors expressing the cytosine deaminase gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild-type tumor. Cancer Res. 54: 1503-1506.
21. 21. VILE, R.G. et al. 1994. Systemic gene therapy for murine melanoma using tissue-specific expression of the HSVtk gene involves an immune component. Cancer Res. 54: 6228-6234.
22. 22. FREEMAN, S.M. et al. 1997. Immune system in suicide gene therapy. Lancet 349: 2-3.
23. 23. MULLEN, C.A. et al. 1996. Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. Cancer Res. 56: 1362-1366.
24. 24. WEI, M.X. et al. 1998. Suicide gene therapy of chemically induced mammary tumor in rat: efficacy and distant bystander effect. Cancer Res. 58: 3529-3532.
25. 25. RAM, Z. et al. 1998. Therapy of malignant brain tumors by intratumoral injection of retroviral vector-producing cells. Nat. Med. 3: 1354-1361.
26. 26. PANDHA, H.S. et al. 1998. Phase 1 trial of genetic prodrug activation therapy for metastatic breast cancer. Submitted for publication.